Sarepta Strategy and Business Model

Executive Overview

Sarepta is a rare-disease biopharmaceutical company focused on precision genetic medicine, with its commercial and clinical identity built primarily around Duchenne muscular dystrophy (DMD). Founded in 1980 and now headquartered in Cambridge, Massachusetts, the company has evolved from an oligonucleotide-focused developer into one of the few biotech companies with both marketed RNA therapies and an approved gene therapy in neuromuscular disease. Its commercial portfolio includes Exondys 51, Vyondys 53, and Amondys 45, which are exon-skipping therapies for defined DMD mutation subsets, and Elevidys, a micro-dystrophin gene therapy that became the company’s most important growth driver after its 2023 launch and 2024 label expansion. Strategically, Sarepta is trying to use its DMD leadership to build a broader genetic-medicine platform spanning RNA, adeno-associated virus gene therapy, and newer modalities such as RNA interference and gene editing partnerships. Commercially, the business remains heavily U.S.-weighted, while Roche supports commercialization of certain gene therapies outside the United States. For FY2024, Sarepta reported revenue of roughly $1.8 billion, reflecting both the durability of its exon-skipping franchise and the scale-up of Elevidys.

Sarepta at a Glance

Logo
Common name	Sarepta
Full legal name	Sarepta Therapeutics, Inc.
Headquarters	Cambridge, Massachusetts, United States
Ownership	Public company; no controlling shareholder apparent
Ticker	SRPT
Exchange	NASDAQ
Market Cap	$1.83B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1980; renamed Sarepta Therapeutics in 2012; Exondys 51 approved in 2016; Elevidys approved in 2023 and expanded in 2024
Industry or industries	Biotechnology; rare-disease therapeutics; genetic medicine
Key products or services	Elevidys, Exondys 51, Vyondys 53, Amondys 45, and genetic-medicine research and development
Geographic footprint	U.S.-centered commercial business with global clinical activity; Roche supports certain gene therapy activities outside the U.S.
Business segments as officially reported	One reportable segment
Company website	https://www.sarepta.com/

1. What Is the Strategy of Sarepta?

Sarepta’s public materials describe a company trying to lead in precision genetic medicine for rare disease, with DMD as the commercial and scientific core. Read through the Playing to Win framework, the strategy is relatively clear: dominate a narrowly defined but high-value disease area, build differentiated scientific capabilities around muscle-targeted genetic medicine, and use that position to expand into adjacent rare neuromuscular diseases and new modalities.

1. 1a. What is the winning aspiration of Sarepta?

   Sarepta’s winning aspiration is not simply to market niche orphan drugs. It is trying to become the leading precision genetic medicine company in rare neuromuscular disease, beginning with DMD and extending into adjacent genetically defined disorders. In management language, success means bringing potentially disease-modifying therapies to patients who historically had few options, while also creating a durable multi-product platform company. In FY2024 and early 2025 communications, the practical expression of that aspiration was the broadening and scaling of Elevidys, continued growth of the exon-skipping franchise, and advancement of next-wave pipeline programs.

2. 1b. Where does Sarepta play?

   Sarepta has chosen to play in rare genetic diseases where the biology is well defined, the patient populations are small but urgent, and specialized commercialization is feasible. DMD is the center of gravity. Within that disease, it plays across both chronic mutation-specific RNA therapies and broader gene-therapy approaches. Beyond DMD, Sarepta has focused on adjacent rare neuromuscular diseases and other areas where its delivery, manufacturing, and regulatory capabilities may be reusable. Geographically, it plays most directly in the United States, while relying on Roche to help extend certain gene therapies outside the U.S.

3. 1c. How does Sarepta plan to win?

   Sarepta’s plan to win combines scientific specialization, first-mover regulatory execution, and high-touch rare-disease commercialization. The company seeks to differentiate through therapies tailored to specific genetic mechanisms, long-standing relationships with DMD specialists and patient communities, and a portfolio approach that spans recurring exon-skipping therapies and one-time gene therapy. The business model also benefits from a strategic sequence: older RNA products created commercial infrastructure and cash flow, while Elevidys and the broader gene-therapy portfolio are intended to move Sarepta toward a larger, more durable franchise. Outside the U.S., Sarepta uses partnership rather than building full commercial infrastructure country by country.

4. 1d. What capabilities must Sarepta have in place?

   To execute this strategy, Sarepta needs a specific set of capabilities: rare-disease clinical development; regulatory skill in accelerated and confirmatory pathways; deep knowledge of muscle biology and genetic targeting; robust chemistry, manufacturing, and controls for both oligonucleotides and viral vectors; specialized market access and patient-support capabilities; and disciplined portfolio management. Manufacturing and quality are especially important because gene therapy scale-up, lot release, and safety monitoring can become bottlenecks even when demand is strong.

5. 1e. What management systems does Sarepta require?

   Sarepta needs management systems that fit a commercial-stage biotech with high scientific complexity. That includes stage-gated portfolio review, quality and compliance controls, pharmacovigilance, post-marketing evidence generation, payer-access management, and capital-allocation discipline. Because the company operates in one reportable segment but across multiple modalities, it also needs cross-functional governance that can balance near-term commercial execution against long-cycle R&D investment. In practice, success depends less on broad corporate bureaucracy and more on tight coordination among clinical, regulatory, technical operations, commercial, and finance teams.

2. What Are the Current Strategic Initiatives of Sarepta?

Based on Sarepta’s latest public disclosures, the company’s current strategic initiatives are concentrated in a few highly specific areas.

• Scale Elevidys after the 2024 FDA label expansion. The June 2024 FDA action materially broadened Elevidys’ commercial opportunity in DMD. Sarepta’s near-term priority has been converting that regulatory expansion into treated-patient volume through site activation, payer access, patient identification, scheduling, and post-treatment monitoring.
• Generate further evidence for Elevidys durability and use across broader patient groups. For a high-cost gene therapy in a closely watched indication, ongoing evidence generation remains strategic, not optional. Sarepta continues to invest in confirmatory, lifecycle, and post-marketing data to support physician confidence, payer access, and regulatory durability.
• Defend and optimize the exon-skipping franchise. Exondys 51, Vyondys 53, and Amondys 45 remain economically important. Sarepta’s task is to preserve treatment continuity in eligible patients, support diagnosis and mutation testing, and maintain specialist confidence even as the franchise matures and the business mix shifts toward gene therapy.
• Expand the platform beyond first-wave DMD products. Sarepta continues to advance pipeline programs in rare neuromuscular disease, including gene therapy and RNA-based approaches. Its late-2024 collaboration with Arrowhead Pharmaceuticals signaled a push to add RNA interference capabilities alongside existing exon-skipping and gene-therapy platforms.
• Strengthen manufacturing, supply, and quality systems. Commercial gene therapy requires a different operating discipline than a chronic specialty drug. Sarepta has emphasized manufacturing readiness, technical operations, quality control, and supply continuity because those functions directly shape launch success and margin profile.
• Build the international opportunity through partnerships. Rather than fully self-commercializing everywhere, Sarepta has relied on Roche to help develop and commercialize certain gene therapies outside the United States. That lowers infrastructure burden but makes alignment on filings, pricing, market access, and launch sequencing strategically important.

3. What Is the Business Model of Sarepta?

What customers actually buy

Sarepta sells prescription therapies for DMD. In practical terms, the economic buyer is usually a payer or hospital channel, the prescribing decision sits with neuromuscular specialists, and the end beneficiary is the patient. Its exon-skipping drugs are chronic therapies for mutation-defined subsets of DMD, while Elevidys is a one-time gene therapy administered through specialized centers.

What portion of the model is recurring or repeat-driven versus one-time

Historically, most of Sarepta’s product revenue has been recurring or repeat-driven because Exondys 51, Vyondys 53, and Amondys 45 are ongoing therapies. Elevidys changes that mix. It is fundamentally a one-time treatment, which makes each patient economically larger but less annuity-like. Over time, Sarepta’s revenue base is likely to become a blend of chronic specialty drug revenue, cohort-based gene therapy launches, and some collaboration-related income.

How pricing power works

Sarepta benefits from orphan-drug economics, small patient populations, and limited direct alternatives in some settings. That supports premium pricing. But pricing power is not unconstrained. It is checked by payer authorization processes, the need for persuasive clinical evidence, public scrutiny around ultra-high-cost therapies, and the operational complexity of treatment delivery.

Why the business mix matters

The mix between PMO-based drugs and gene therapy matters because it changes revenue timing, cost structure, and investor expectations. A chronic RNA-therapy franchise can look more predictable. A gene-therapy business can scale quickly but depends more on site capacity, treatment timing, label breadth, and long-term evidence. Sarepta is managing exactly that transition.

What drives gross margin, operating margin, and cash generation

Gross margin depends on product mix, manufacturing yield, raw-material sourcing, and the economics of internal versus external production. Operating margin is heavily affected by R&D spending, commercialization costs for a specialist field force, medical affairs, and quality systems. Cash generation depends not only on revenue growth but also on working-capital discipline, collections from high-value therapies, and the scale of ongoing pipeline investment.

Revenue model

Sarepta’s revenue model is primarily product sales, supplemented by collaboration economics tied to partnerships such as Roche. It is not a subscription or usage-based model. Instead, it is a regulated biopharma model with high-value treatment episodes, reimbursement complexity, and long development cycles.

4. What Products and/or Services Does Sarepta Sell?

The company does not sell broad consumer health products or diversified pharma services. Its business is concentrated in a small number of very high-value genetic medicines. In economic terms, the most important offerings are Elevidys and the exon-skipping DMD franchise. The older PMO products still matter because they generate recurring revenue and preserve prescriber relationships. The newer growth story is gene therapy and adjacent platform expansion into other rare neuromuscular diseases.

Beyond marketed products, Sarepta’s development pipeline is strategically important. It includes programs in gene therapy, RNA-based therapeutics, and partnered next-generation modalities such as RNA interference. For Sarepta, pipeline assets are not side projects; they are the mechanism by which the company tries to avoid becoming a single-franchise rare-disease specialist.

5. What Are the Key Competitors or Peers of Sarepta?

Sarepta’s competitive set is unusual. Competition is partly product-by-product, partly platform-by-platform, and partly disease-by-disease. In DMD, some rivals are direct program competitors; others are better understood as adjacent muscle-disease or rare-genetic-medicine peers.

• Dyne Therapeutics — A muscle-disease biotech developing targeted oligonucleotide therapies, including a DMD exon 51 program; one of the more relevant emerging competitors in RNA-based muscle therapeutics.
• Avidity Biosciences — Uses antibody-oligonucleotide conjugates to improve tissue delivery in muscle disease; a close technology peer in next-generation RNA therapeutics.
• Wave Life Sciences — Develops stereopure oligonucleotides and has pursued DMD-related and RNA-editing approaches; relevant where mutation-specific RNA therapies compete for specialist attention and capital.
• PepGen — Focused on enhanced delivery peptide-conjugated oligonucleotides for neuromuscular disease; a meaningful platform competitor in DMD and related indications.
• Entrada Therapeutics — Another next-generation intracellular-delivery player with programs in DMD; competes more as a future platform challenger than as a current broad commercial rival.
• Solid Biosciences — Best known for DMD gene-therapy efforts and broader muscle-disease ambitions; one of the clearest direct comparables in gene therapy for muscular disorders.
• Capricor Therapeutics — Focused on DMD through a different modality, including cell therapy for DMD-related cardiac disease; more of an adjacent competitor than a like-for-like substitute.
• PTC Therapeutics — A rare-disease biotech with long-standing ties to the DMD market, particularly outside the United States; less of a direct U.S. commercial competitor today but still a relevant DMD peer.
• Ultragenyx Pharmaceutical — Not a direct DMD rival across every program, but a close peer in rare-disease commercialization, genetic medicine, and orphan-drug portfolio building.
• BioMarin Pharmaceutical — Another important rare-disease peer with experience scaling highly specialized therapies and navigating reimbursement for transformative treatments.

A large pharmaceutical company could also become a competitor through licensing or acquisition of a muscle-disease platform, so Sarepta’s real competitive environment includes both current biotech peers and potential future entrants with larger balance sheets.

6. What Is the Marketing Strategy of Sarepta?

Sarepta’s marketing strategy is that of a specialist rare-disease company, not a mass-market pharmaceutical brand. The center of gravity is physician education, patient identification, market access, and account support rather than consumer advertising.

• Medical and scientific engagement is central. In DMD, prescribing is concentrated among neuromuscular specialists and expert centers. That makes peer-reviewed data, conference presence, medical affairs, and specialist credibility more important than broad brand advertising.
• Patient and caregiver engagement matters. In rare disease, advocacy groups, diagnostic pathways, and family decision-making are highly influential. Sarepta therefore needs strong patient-services infrastructure and clear communication around treatment logistics, not just promotional messaging.
• Market access is part of marketing. For therapies with high cost and specialized administration, payer engagement and reimbursement support are inseparable from commercial success.
• Field execution is account based. Elevidys in particular requires coordination with hospitals, infusion centers, and treatment sites. That means the “marketing” challenge is partly operational: site readiness, scheduling, protocol familiarity, and confidence in safety monitoring.

Brand marketing is therefore a supporting capability, not the main differentiator. Sarepta wins more through evidence, relationships, treatment access, and execution than through classic promotional scale.

7. What Are the Key Customer Segments of Sarepta?

Sarepta serves a narrow end market but a complex stakeholder set.

• DMD patients and families — They are the ultimate users and decision influencers. Because DMD is a devastating rare disease, treatment urgency, caregiver education, and support services matter greatly.
• Neuromuscular specialists and academic treatment centers — These physicians and centers drive diagnosis, mutation testing, treatment choice, and long-term monitoring.
• Hospitals, infusion centers, and gene-therapy sites — Especially important for Elevidys, where treatment administration and monitoring occur in specialized settings.
• Payers and reimbursement decision makers — Commercial insurers, Medicaid programs, and related reviewers are economically critical because they determine access, prior authorization, and treatment timing.
• Specialty pharmacies and specialty distributors — Important channel partners for the exon-skipping portfolio and certain fulfillment processes.
• International commercialization partners — Outside the U.S., partners such as Roche are economically significant because they shape regulatory and commercial reach for certain gene therapies.

Sarepta is diversified across stakeholders but not across end markets. Its commercial exposure remains highly concentrated in DMD, which creates both focus and dependence.

8. What Is the Sales Model of Sarepta?

Sarepta uses a high-touch specialty-biopharma sales model.

In the United States, the company markets directly to neuromuscular specialists, treatment centers, and payer stakeholders through a specialized commercial organization. Its field model is closer to account management than to broad pharmaceutical detailing. That is especially true for Elevidys, where sales depend on site onboarding, treatment coordination, reimbursement support, and confidence in administration protocols.

For the exon-skipping therapies, Sarepta relies on specialty distribution and specialty pharmacy channels suited to high-cost rare-disease medicines. Those channels support recurring therapy logistics, reimbursement coordination, and continuity of care. For gene therapy, the route to market is more site-centric: activated hospitals and treatment centers become the effective commercial nodes.

Outside the United States, Sarepta has not tried to replicate a full standalone commercial infrastructure everywhere. Instead, it has partnered, most notably with Roche for certain gene-therapy territories. That channel structure can improve geographic reach and reduce fixed cost, but it also means Sarepta gives up some direct customer intimacy and must manage partnership alignment carefully.

9. In What Geographies Does Sarepta Operate?

Sarepta’s operational base is centered in the United States, and its commercial business remains primarily U.S.-weighted. The company is headquartered in Cambridge, Massachusetts, and has built U.S.-based capabilities across research, technical operations, manufacturing oversight, and commercial support.

Its customer reach extends beyond the U.S. in two ways. First, Sarepta runs clinical development and regulatory activities across multiple countries, as is typical for rare-disease studies and global registration strategy. Second, through Roche and other partners, it has a route to commercialize certain gene therapies outside the United States. That gives Sarepta exposure to Europe, Latin America, Asia-Pacific, and other international markets without requiring the company to build a full local operating stack in every geography.

The practical reality is that Sarepta is globally relevant but not globally balanced. The U.S. remains the core profit pool and operational center of gravity.

10. Who Are the Owners of Sarepta?

Sarepta is a publicly traded company. Based on public ownership disclosures available in 2025, its shareholder base is predominantly institutional, with large asset managers such as The Vanguard Group, BlackRock, and State Street among the notable holders. No controlling shareholder appears to exist. As with many biotechnology companies, the ownership mix can shift meaningfully over time as clinical, regulatory, and commercial milestones change the company’s risk profile.

11. How Is Sarepta Organized?

Officially, Sarepta reports one reportable segment. Practically, however, the business can be understood as a few interlocking operating groups.

• Commercial DMD franchise — The U.S. business supporting Exondys 51, Vyondys 53, Amondys 45, and Elevidys.
• Research and development — Platform and program teams spanning RNA, gene therapy, and newer modalities.
• Technical operations and manufacturing — Responsible for process development, production oversight, quality, supply, and release.
• Regulatory, medical, and safety functions — Especially important given the complexity of gene-therapy approvals and post-marketing obligations.
• Corporate functions — Finance, legal, human resources, business development, and alliance management.

The company also has an important partnership overlay. Roche plays a major role in the ex-U.S. development and commercialization of certain gene therapies, so alliance management is not peripheral; it is part of the operating model.

12. How Does Sarepta Operate?

Sarepta operates as a commercial-stage genetic-medicine company with a value chain that runs from molecular design through long-term patient monitoring.

1. Target selection and therapy design — Sarepta starts with genetically defined diseases, especially those where restoring or modifying protein expression may change outcomes.
2. Clinical development — Because patient populations are small, trial design, natural-history data, biomarker strategy, and regulatory interaction are unusually important.
3. Manufacturing and technical operations — The company must manage distinct manufacturing needs for oligonucleotide drugs versus viral-vector gene therapies, each with different yields, release testing, and supply risks.
4. Regulatory and reimbursement execution — Approval alone is not enough. Sarepta must also secure payer access and support treatment-center readiness.
5. Distribution and administration — Chronic PMO therapies move through specialty channels, while Elevidys requires treatment-site coordination and monitoring.
6. Post-market evidence and safety monitoring — Especially in gene therapy, real-world data, follow-up, and pharmacovigilance remain core operating activities.

The main operational complexities are not generic pharmaceutical ones. They are rare-disease specific: small patient populations, genotype-specific diagnosis, limited site capacity, complex payer review, manufacturing sensitivity, and the need to coordinate many stakeholders around each treatment event.

13. What Are the Growth Opportunities for Sarepta?

Sarepta has several plausible growth avenues, but each comes with meaningful execution risk.

• Broader Elevidys penetration in the U.S. The biggest near-term opportunity is converting the broader 2024 label into higher patient throughput. That depends on payer coverage, site capacity, and continued physician confidence.
• International expansion of gene therapy. Through Roche, Sarepta can pursue approvals and launches beyond the United States without building a fully independent infrastructure in every market.
• Earlier diagnosis and patient finding. In rare disease, better genetic testing and diagnostic awareness can expand the treated population even without any change in incidence.
• Lifecycle expansion in DMD. More evidence, broader use, and better care-pathway integration could improve adoption and durability of the current portfolio.
• Pipeline expansion beyond DMD. Sarepta’s longer-term value depends on translating its capabilities into other rare neuromuscular diseases and additional genetic targets.
• New modalities and external innovation. The company’s move into RNA interference and gene-editing partnerships suggests a desire to widen its technology base rather than rely only on PMO and AAV approaches.

The main constraints are equally clear: safety concerns in gene therapy, regulatory uncertainty, manufacturing scale and quality, intense payer scrutiny around very high-cost treatments, small addressable populations, and strong emerging competition in muscle disease RNA therapeutics.

14. What Is the History of Sarepta?

Sarepta was founded in 1980 and originally operated under earlier corporate names before becoming Sarepta Therapeutics in 2012. The company’s history is notable for a major strategic transformation: it moved away from earlier antiviral roots and became a rare-disease genetic-medicine specialist built around morpholino chemistry and, later, gene therapy.

A defining moment came in 2016, when the U.S. Food and Drug Administration approved Exondys 51 for a subset of DMD patients. That approval was widely watched and controversial, but it established Sarepta as a real commercial company and gave it a durable foothold in DMD. Sarepta then expanded its mutation-specific franchise with Vyondys 53 in 2019 and Amondys 45 in 2021.

The next major chapter was gene therapy. In 2019, Sarepta entered a major global collaboration with Roche covering certain gene therapies outside the U.S., underscoring the strategic importance of its micro-dystrophin platform. In 2023, Elevidys received its first FDA approval, and in 2024 the label was broadened significantly. That sequence moved Sarepta from being an exon-skipping specialist to a company trying to lead the DMD treatment landscape across multiple modalities.

15. What Are the Key Suppliers to Sarepta?

Suppliers matter materially to Sarepta because its products depend on specialized manufacturing inputs and services that are not easily interchangeable.

The most important supplier categories include:

• Oligonucleotide raw materials and manufacturing inputs for the exon-skipping franchise
• Plasmids, viral-vector inputs, and single-use bioprocess materials for gene therapy manufacturing
• Contract development and manufacturing organizations for production, process support, and scale-up
• Sterile fill-finish providers and analytical testing partners
• Cold-chain and specialty logistics providers for handling high-value biologic products
• Specialty distribution and pharmacy partners for commercial fulfillment

Like many biotech companies, Sarepta has disclosed reliance on sole-source or limited-source suppliers for certain materials and services, even if public filings do not provide a complete named supplier list. Strategically, supplier structure matters because any disruption in a critical raw material, release-testing workflow, or fill-finish step can directly affect revenue, patient scheduling, and regulatory compliance.

16. What Are the Key Brands Owned by Sarepta?

Branding matters at Sarepta, but in a specialist way. The company’s brands are physician- and patient-community brands rather than mass-market consumer brands.

• Elevidys — Sarepta’s flagship growth brand. It is positioned as a potentially transformative gene therapy in DMD and is central to the company’s current strategic narrative.
• Exondys 51 — The foundational Sarepta brand and the product most associated with the company’s emergence as a commercial rare-disease biotech.
• Vyondys 53 — A mutation-specific extension of the exon-skipping franchise for exon 53-amenable patients.
• Amondys 45 — Another mutation-specific DMD brand, reinforcing Sarepta’s position in genetically targeted care.

In Sarepta’s market, brand strength comes less from advertising and more from clinical data, label scope, reimbursement support, specialist familiarity, and trust with patient communities. The corporate brand also matters because families and physicians often engage with Sarepta across multiple products and long treatment journeys.

17. How Does the Supply Chain of Sarepta Function?

Sarepta’s supply chain has to support two very different product types: chronic exon-skipping therapies and one-time gene therapy.

For the exon-skipping portfolio, the core supply-chain tasks include sourcing specialized chemical inputs, manufacturing the active pharmaceutical ingredient, sterile fill-finish, quality release, specialty distribution, and recurring delivery to treatment sites. Reliability and continuity are critical because these therapies are administered over time and interruption can disrupt patient care.

For Elevidys, the supply chain is more complex. It includes highly specialized upstream and downstream manufacturing steps, extensive testing and release procedures, cold-chain requirements, treatment-site scheduling, and coordination with centers that administer the therapy. Because gene therapy involves large-value individual treatment events, supply reliability is linked directly to revenue timing.

Procurement, inventory planning, and logistics therefore function as strategic capabilities. Sarepta cannot treat supply chain as a back-office activity. In its business, supply chain affects access, margin, launch velocity, and physician confidence.

18. What Are the Key Assets of Sarepta?

Sarepta’s most important assets are a mix of intangible and operating assets rather than just physical plant.

• Approved product labels for its DMD portfolio, especially Elevidys and the exon-skipping drugs
• Intellectual property and know-how in phosphorodiamidate morpholino oligomer chemistry, muscle-directed genetic medicine, and manufacturing processes
• Clinical and regulatory data packages supporting current approvals and future label expansion efforts
• Commercial relationships with neuromuscular specialists, treatment centers, and patient communities
• Technical operations and manufacturing capabilities including internal expertise and qualified external production networks
• Strategic partnerships such as the Roche collaboration, which extends Sarepta’s reach outside the U.S.
• Pipeline assets in DMD and adjacent rare diseases

Compared with an airline or a miner, Sarepta is not asset-heavy in the classic fixed-asset sense. But it is economically asset-intensive in a different way: the value of its IP, approvals, manufacturing know-how, and clinical evidence base is extremely high and forms a meaningful barrier to entry.

19. What Is the Technology Strategy of Sarepta?

Sarepta’s technology strategy is fundamentally a modality strategy. The company is not trying to be a generic digital-health or software business. Its technology agenda is about building and combining genetic-medicine platforms that can address rare neuromuscular disease more effectively.

The main pillars are:

• Exon-skipping oligonucleotide technology — The foundation of Sarepta’s original commercial success in DMD.
• Adeno-associated virus gene therapy — Most visibly embodied in Elevidys and related programs.
• Next-generation RNA modalities — Including the addition of RNA interference capabilities through collaboration.
• Gene editing partnerships — Relevant to longer-term platform expansion even where those programs are earlier stage.

Internally, technology also matters in manufacturing analytics, assay development, process control, and long-term data generation. In Sarepta’s case, technology is both the product and the production system. Competitiveness depends on choosing the right modality for a disease, delivering it effectively to muscle tissue, and manufacturing it reproducibly at commercial quality.

20. What Is the R&D Strategy of Sarepta?

R&D is central to Sarepta’s identity and valuation. The company’s strategy is to invest heavily in genetic-medicine innovation within a relatively narrow disease focus, rather than spread R&D capital across many unrelated therapeutic areas.

Several features define the approach:

• Disease concentration with platform breadth. Sarepta stays focused on rare genetic muscle disease, but uses multiple modalities within that focus.
• Lifecycle evidence generation. Even after approval, the company continues to invest in confirmatory and follow-up studies because regulatory durability and reimbursement depend on ongoing evidence.
• Platform reuse. Scientific, regulatory, and manufacturing knowledge developed in DMD can potentially be reused in adjacent indications.
• External innovation. Sarepta uses collaborations to add capabilities it does not want to build entirely from scratch.
• Biomarker- and mechanism-driven development. In rare disease, clear mechanistic rationale and measurable biologic effect are especially important.

Sarepta’s major innovations to date include its PMO-based exon-skipping franchise and the development of a commercially approved micro-dystrophin gene therapy. The R&D challenge now is to turn those scientific wins into a broader and more durable platform without overextending capital.

21. What Is the Finance Strategy of Sarepta?

Sarepta’s finance strategy is built around funding a very large innovation agenda from a still-concentrated commercial base. That creates a few clear priorities.

• Preserve liquidity while investing for growth. Sarepta needs enough balance-sheet flexibility to absorb clinical, regulatory, and manufacturing volatility while continuing to fund R&D and launch activity.
• Use commercial cash flows to support pipeline expansion. The exon-skipping franchise and Elevidys are not only products; they are financing engines for broader platform development.
• Allocate capital toward internal R&D, manufacturing readiness, and selective business development. Sarepta has generally favored reinvestment over dividends or broad shareholder distributions.
• Manage a biotech-style capital structure. Like many commercial-stage biotech companies, Sarepta has used a mix of cash on hand, collaboration economics, and debt or equity-linked financing to support its strategy.

Margin expansion is possible if Elevidys scales well and manufacturing becomes more efficient, but Sarepta is still in a phase where operating leverage competes with heavy ongoing investment. That makes finance strategy inseparable from portfolio prioritization.

22. What Major Acquisitions Has Sarepta Made?

Acquisitions have played a secondary role in Sarepta’s growth relative to internal R&D and partnerships. The company has generally relied more on licensing, collaboration, and selective dealmaking than on large-scale M&A.

The clearest example is Myonexus Therapeutics, which Sarepta acquired in 2019 to add limb-girdle muscular dystrophy gene-therapy programs. That deal fit Sarepta’s strategy of staying close to neuromuscular disease while extending its gene-therapy footprint.

By contrast, some of the company’s most strategically important transactions were not acquisitions. The 2019 Roche collaboration around certain gene therapies outside the U.S. and the late-2024 Arrowhead collaboration in RNA interference were partnership moves rather than full takeovers. That distinction matters: Sarepta appears to prefer capability access and geographic leverage without always absorbing the full cost and integration burden of large acquisitions.

23. How Companies Like Sarepta Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Sarepta use Umbrex when they want senior-caliber strategy and execution support without hiring a full consulting team with the associated overhead. For a company navigating gene-therapy scale-up, rare-disease commercialization, platform R&D choices, and global partnering, that model fits especially well.

Representative projects Umbrex consultants could support for a company like Sarepta include:

• Elevidys market expansion plan — Assess site-of-care capacity, referral leakage, patient journey bottlenecks, and payer approval cycle time to accelerate treatment throughput.
• DMD patient-finding strategy — Map diagnostic pathways, mutation-testing gaps, and neuromuscular referral flows to improve identification of eligible patients.
• Rare-disease pricing and market-access strategy — Refine value story, evidence needs, and contracting approaches for commercial payers and Medicaid stakeholders.
• Gene-therapy operations redesign — Improve the operating model across site activation, scheduling, logistics, medical affairs, and post-treatment monitoring.
• Manufacturing and supplier risk assessment — Evaluate single-source exposure, CDMO strategy, tech-transfer priorities, and contingency planning for critical inputs.
• Portfolio prioritization across modalities — Create a decision framework for allocating capital among PMO, gene therapy, RNA interference, and gene-editing programs.
• International launch sequencing support — Help coordinate with partners such as Roche on country prioritization, pricing logic, and launch-readiness milestones.
• Commercial organization design — Rework field roles, account management, analytics, and medical-commercial interfaces as the business mix shifts from chronic therapy to gene therapy.
• Business development and acquisition diligence — Evaluate external rare-disease assets, platform partnerships, or tuck-in acquisitions in muscle disease and adjacent genetic conditions.
• Finance and scenario planning — Build revenue, margin, and cash-use scenarios tied to Elevidys uptake, manufacturing yields, pipeline timing, and partnership economics.